These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Neuromuscular and mitochondrial disorders: what is relevant to the anaesthesiologist? Driessen JJ Curr Opin Anaesthesiol; 2008 Jun; 21(3):350-5. PubMed ID: 18458553 [TBL] [Abstract][Full Text] [Related]
28. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met. Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814 [TBL] [Abstract][Full Text] [Related]
29. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family. Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752 [TBL] [Abstract][Full Text] [Related]
30. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia. Dexter F; Epstein RH; Wachtel RE; Rosenberg H Anesth Analg; 2013 Jan; 116(1):118-22. PubMed ID: 23223104 [TBL] [Abstract][Full Text] [Related]
31. A case of discordance between genotype and phenotype in a malignant hyperthermia family. Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931 [TBL] [Abstract][Full Text] [Related]
32. Case report: Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old. Lavezzi WA; Capacchione JF; Muldoon SM; Sambuughin N; Bina S; Steele D; Brandom BW Anesth Analg; 2013 Feb; 116(2):420-3. PubMed ID: 23267001 [TBL] [Abstract][Full Text] [Related]
33. [Application of caffeine-halothane contracture test in the diagnosis of malignant hyperthermia]. Wang YL; Guo XY; Xu ZH; Huang YG; Luo AL Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Apr; 30(2):182-6. PubMed ID: 18505122 [TBL] [Abstract][Full Text] [Related]
35. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model. Wehner M; Rueffert H; Koenig F; Olthoff D Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166 [TBL] [Abstract][Full Text] [Related]
36. Identification of malignant hyperthermia-susceptible ryanodine receptor type 1 gene (RYR1) mutations in a child who died in a car after exposure to a high environmental temperature. Nishio H; Sato T; Fukunishi S; Tamura A; Iwata M; Tsuboi K; Suzuki K Leg Med (Tokyo); 2009 May; 11(3):142-3. PubMed ID: 19223216 [TBL] [Abstract][Full Text] [Related]
37. [ENT anesthesia: the German Society of Anesthesia and Intensive Care Medicine on the use of succinylcholine]. HNO; 1995 Nov; 43(11):640-1. PubMed ID: 8530309 [No Abstract] [Full Text] [Related]
38. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. Censier K; Urwyler A; Zorzato F; Treves S J Clin Invest; 1998 Mar; 101(6):1233-42. PubMed ID: 9502764 [TBL] [Abstract][Full Text] [Related]
39. Novel ryanodine receptor mutation that may cause malignant hyperthermia. Kaufmann A; Kraft B; Michalek-Sauberer A; Weigl LG Anesthesiology; 2008 Sep; 109(3):457-64. PubMed ID: 18719443 [TBL] [Abstract][Full Text] [Related]